age-related macular degeneration

News

Astellas cuts $5.9bn deal to buy Iveric Bio

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,

News

French court overturns €444m fine for Novartis, Roche

Says companies did not abuse a market position to push Lucentis over off-label Avastin in AMD.

Views & Analysis

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Last month, pharmaphorum spoke with Dr Charles C.

News

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.

News

FDA clears Roche's Susvimo implant for eye disease wet AMD

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular inj

News

FDA OKs first biosimilar of Roche's blockbuster AMD drug Luc...

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis' Lucentis (ranibizumab) for leading causes of blindness, raising the prospect o

Astellas cuts $5.9bn deal to buy Iveric Bio

French court overturns €444m fine for Novartis, Roche

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

FDA clears Roche's Susvimo implant for eye disease wet AMD

FDA OKs first biosimilar of Roche's blockbuster AMD drug Luc...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

age-related macular degeneration

Editor's Picks